Premium
[O4–02–05]: UNBIASED BIOMARKER‐BASED CATEGORIZATION OF A MULTICENTER COHORT OF ADD, MCI AND FTD PATIENTS
Author(s) -
Toschi Nicola,
Lista Simone,
Baldacci Filippo,
Blennow Kaj,
Zetterberg Henrik,
Kilimann Ingo,
Teipel Stefan J.,
Cavedo Enrica,
Melo dos Santos Antonio,
Lamari Foudil,
Dubois Bruno,
Floris Roberto,
Garaci Francesco,
Hampel Harald
Publication year - 2017
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2017.07.428
Subject(s) - neurogranin , biomarker , dementia , frontotemporal dementia , neurodegeneration , cohort , psychology , medicine , neuroscience , oncology , chemistry , physics , disease , nuclear magnetic resonance , biochemistry , protein kinase c , enzyme
with multiple cognitive and imaging measures, including MMSE (Spearman’s rho1⁄4 0.62, p1⁄40.0001), CDR SOB (rho1⁄40.79, p<0.0001), baseline brain volume (rho1⁄4 0.62, p1⁄40.0002), and subsequent rate of brain atrophy (rho1⁄40.53, p1⁄40.01). Conclusions: Serum NfL concentration is increased in FAD prior to symptom onset and correlates with measures of disease stage and severity. Serum NfL may thus be a feasible biomarker of early AD-related neurodegeneration, with potential utility in both clinical practice and in presymptomatic trials.